NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO)

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
 Novartis Pharmaceuticals (ranibizumab) 	Board of Community Health Councils in Wales Dride National Formula Telephone
Patient/carer groups	British National Formulary Care Quality Commission
 Action for Blind People 	Care Quality Commission
Action for Blind Feople Afiya Trust	 Commissioning Support Appraisals Service
Association of Blind Asians (ABA)	 Department of Health, Social Services
Black Health Agency	and Public Safety for Northern Ireland
Chinese National Healthy Living Centre	 Medicines and Healthcare products Regulatory Agency
Counsel and Care	 National Association of Primary Care
Equalities National Council	NHS Alliance
Eyecare Trust	 NHS Commercial Medicines Unit
Fight for Sight	NHS Confederation
Macular Disease Society	 NHS Quality Improvement Scotland
Muslim Council of Britain	 Public Health Wales NHS Trust
Muslim Health Network	 Scottish Medicines Consortium
 Organisation of Blind African 	
Caribbeans	Comparator manufacturers
Royal National Institute of Blind	 Allergan (dexamethasone implant)
People (RNIB)	Carl Zeiss (photocoagulation)
SeeAbility	Coherent UK (photocoagulation)
• Sense	KLS Martin Group (photocoagulation)
South Asian Health Foundation	Litechnica (photocoagulation)
Specialised Healthcare Alliance	Lumenis (UK) (photocoagulation)
Thomas Pocklington Trust	Quantel Medical (photocoagulation)
Drefessional groups	Roche Products (bevacizumab)
<u>Professional groups</u>British Association for Services to the	Topcon Great Britain (photocoagulation)
British Association for Services to the Elderly	Polovant recearch groups
British Geriatrics Society	Relevant research groups
 British Ophthalmic Anaesthesia 	 Institute of Ophthalmology, University College London
Society (BOAS)	MRC Clinical Trials Unit

National Institute for Health and Clinical Excellence

Matrix for the single technology appraisal of ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO)

Issue date: March 2011 Page 1 of 3

Consultees Commentators (no right to submit or appeal) National Institute for Health Research College of Optometrists Royal College of General Practitioners Policy Research Institute on Ageing and Royal College of Nursing **Ethnicity** Royal College of Ophthalmologists Research Institute for the Care of Older People Royal College of Pathologists Royal College of Physicians **Evidence Review Group** Royal Pharmaceutical Society Aberdeen HTA Group Royal Society of Medicine -National Institute for Health Research Intellectual Disabilities Forum Health Technology Assessment United Kingdom Clinical Pharmacy Programme Association Associated Guideline Groups Others National Clinical Guidelines Centre Department of Health Welsh Assembly Government Associated Public Health Groups Wiltshire PCT None Wirral PCT

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence Matrix for the single technology appraisal of ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO)

Issue date: March 2011 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence Matrix for the single technology appraisal of ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO)

Issue date: March 2011 Page 3 of 3

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.